Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Their website literature explains they did a validation with symptomatic patients 5 days from onset. So basically the test is very sensitive with that group. But when you use it for mass screening i.e with people who for the most part don't have symptoms its not that sensitive at all. Good enough to get some unknown carriers isolated but plenty of room for Avacta to do much better even using a swab method.
I think the small evaluation is to get a clear conclusion on whether its good enough to do tech transfer. If it is then large number of samples from tech transfer will be used for clinical validation. Both of these are being done on Avactas behalf and what Avacta may or may not do through rhe govmt process is a separate issue.
The tender mentions many reagents so the mention of affimers is merely reassuring therefore. What else is new, if anything? Havent seen anything and seems like weve now had a dump after this merry pump.
Yes and the update yesterday shows we have moved on through analytical validation. The small upcoming study, if the results are good, will mark design freeze, with tt and full clinical validation hot on heels.
Agreed Chris. And now rather simply awaiting that Avacta are gonna do a small evaluation to get us performance figures within the next few weeks. Assuming those figures are as good as expected the sp will start a transformative journey.
Is anyone definitively confident what the sensitivity is then? Dont forget innovas is only actually 74 per cent when used for mass general pop testing. I reckon that leave us a large margin to be better
I agree with Hants that it sounds like the device making part of the tt has been cracked including its mass manufacturability. They have to get the sample collection bit right but that should be routine for the swab. And on the saliva the directors talk says they've made good technical progress. The strategy is good. They make progress by starting evaluation of swab soon, finishing up tech transfer and then probably getting clinical validation done by late december still. Then income generating large scale pilots n January. Yes that would be for a swab based test but due to affimers they should be able to comfortably surpass innovas 74 / 57 figures. And they can get on with manufacturing at scale , suppressing r and making profit. Then when a saliva based collection approach is perfected they can ramp the collection kit to go alongside the already ramped up devices and we can all hopefully then say the best just got better rather than moaning why it took so long.
Its mid December 2020 and Private Ryan is now nearly 100 and living in England with his Yorkshire wife. He used to look forward to Christmas. But this year fills him with dread. To think he fought a terrible war only for a bunch of covidiots to go and mess the r rate up again. Now his great grandson wants to come and visit down from Uni for the festivities. The latest in the papers says that his grandson might need to do once a day tests for a week just to visit. They must be cheap and nasty tests he thought to himself. If only there was a company who could do better? Then he comes across an article in the Yorkshire post about a company down the road in Wetherby. Apparently they have a magic Yorkshire made ingredient in their test which according to the article had just been shown to have amazing sensitivity. One or two of these tests would be plenty he thought. They might not be out in time for Christmas but will give everyone a happy new year.
Sovereign is important but so is the likely superior performance of an affimer based test when it comes to picking up pre and a symptomatics. How did innova go from advertising 94 per cent sensitive on its website to a real world professional superbised sensitivity of 74? Easy. The 94 must have been achieved by looking at samples from symptomatics and if you read the website its only intended for this group. So when you use it for the mass screen purpose instead of course the sensitivity figures drop.